AR133383A1 - Anticuerpos que se unen a cd3 - Google Patents
Anticuerpos que se unen a cd3Info
- Publication number
- AR133383A1 AR133383A1 ARP240101982A ARP240101982A AR133383A1 AR 133383 A1 AR133383 A1 AR 133383A1 AR P240101982 A ARP240101982 A AR P240101982A AR P240101982 A ARP240101982 A AR P240101982A AR 133383 A1 AR133383 A1 AR 133383A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- antibody
- antibodies
- lcdr
- hcdr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere generalmente a anticuerpos que se unen a CD3, incluso anticuerpos multiespecíficos, por ejemplo, para activar linfocitos T. Además, la presente invención se refiere a polinucleótidos que codifican tales anticuerpos, y vectores y células huésped que comprenden tales polinucleótidos. La invención se refiere además a métodos para producir los anticuerpos, y a métodos para usarlos en el tratamiento de una enfermedad. Reivindicación 1: Un anticuerpo que se une a CD3, en donde el anticuerpo comprende un primer dominio de unión al antígeno, que comprende (i) una región variable de la cadena pesada (VH) que comprende una región determinante de la complementariedad de la cadena pesada (HCDR) 1 de SEQ ID Nº 1, una HCDR 2 de SEQ ID Nº 9, SEQ ID Nº 13 o SEQ ID Nº 15, y una HCDR 3 de SEQ ID Nº 3, y (ii) una región variable de la cadena liviana (VL) que comprende una región determinante de la complementariedad de la cadena liviana (LCDR) 1 de SEQ ID Nº 5, una LCDR 2 de SEQ ID Nº 11 y una LCDR 3 de SEQ ID Nº 7. Reivindicación 22: Un polinucleótido aislado que codifica el anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 - 21. Reivindicación 23: Una célula huésped que comprende el polinucleótido aislado de acuerdo con la reivindicación 22. Reivindicación 24: Un método para producir un anticuerpo que se une a CD3, que comprende las etapas de (a) cultivar la célula huésped de acuerdo con la reivindicación 23 en condiciones adecuadas para la expresión del anticuerpo y opcionalmente (b) recuperar el anticuerpo. Reivindicación 25: Un anticuerpo que se une a CD3, producido mediante el método de acuerdo con la reivindicación 24. Reivindicación 26: Una composición farmacéutica que comprende el anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 - 21 o 25 y un portador farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23187733 | 2023-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133383A1 true AR133383A1 (es) | 2025-09-24 |
Family
ID=87473964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101982A AR133383A1 (es) | 2023-07-26 | 2024-07-26 | Anticuerpos que se unen a cd3 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250092136A1 (es) |
| EP (1) | EP4750532A1 (es) |
| KR (1) | KR20260044221A (es) |
| CN (1) | CN121712799A (es) |
| AR (1) | AR133383A1 (es) |
| AU (1) | AU2024300993A1 (es) |
| CL (1) | CL2026000173A1 (es) |
| CO (1) | CO2026000799A2 (es) |
| CR (1) | CR20260033A (es) |
| IL (1) | IL325601A (es) |
| MX (1) | MX2026000851A (es) |
| PE (1) | PE20260581A1 (es) |
| TW (1) | TW202519549A (es) |
| WO (1) | WO2025021838A1 (es) |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2378403A1 (en) | 1999-07-26 | 2001-02-01 | Genentech, Inc. | Novel polynucleotides and method for the use thereof |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
| WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
| WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| KR101498588B1 (ko) | 2003-01-22 | 2015-03-05 | 로슈 글리카트 아게 | 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도 |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| BRPI0607315B1 (pt) | 2005-02-07 | 2022-05-17 | Roche Glycart Ag | Molécula de ligação ao antígeno anti-egfr humanizada e seus usos, composição farmacêutica, e método para detectar a presença de egfr em uma amostra |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US20080044455A1 (en) | 2006-08-21 | 2008-02-21 | Chaim Welczer | Tonsillitus Treatment |
| EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
| PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| SG176219A1 (en) | 2009-05-27 | 2011-12-29 | Hoffmann La Roche | Tri- or tetraspecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| CN102712696A (zh) | 2009-09-16 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 包含卷曲螺旋和/或系链的蛋白质复合体及其用途 |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| CA3220104A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| LT2748201T (lt) | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
| KR101870555B1 (ko) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| KR101721301B1 (ko) | 2011-08-23 | 2017-03-29 | 로슈 글리카트 아게 | 이중특이적 항원 결합 분자 |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| KR102069397B1 (ko) | 2012-02-15 | 2020-01-22 | 에프. 호프만-라 로슈 아게 | Fc-수용체 기재 친화성 크로마토그래피 |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| BR112016011027A2 (pt) | 2013-12-20 | 2017-12-05 | Genentech Inc | método de produção de um anticorpo, anticorpos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, método de tratamento de asma e método de tratamento de um distúrbio |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| EP3174897B1 (en) | 2014-07-29 | 2020-02-12 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| PL3177643T3 (pl) | 2014-08-04 | 2019-09-30 | F.Hoffmann-La Roche Ag | Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T |
| JP2017531620A (ja) | 2014-09-12 | 2017-10-26 | ジェネンテック, インコーポレイテッド | システイン操作抗体及びコンジュゲート |
| CA2980189A1 (en) | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
| ES3043088T3 (en) * | 2015-06-17 | 2025-11-24 | Hoffmann La Roche | Anti-her2 antibodies and methods of use |
| SG11202102859TA (en) * | 2018-12-21 | 2021-04-29 | Hoffmann La Roche | Antibodies binding to cd3 |
| CN121577898A (zh) | 2020-04-08 | 2026-02-27 | 豪夫迈·罗氏有限公司 | 大分子非特异性清除测定 |
| IL296089A (en) | 2020-06-19 | 2022-11-01 | Hoffmann La Roche | Antibodies bind to cd3 |
| WO2021255146A1 (en) * | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
-
2024
- 2024-07-24 PE PE2026000138A patent/PE20260581A1/es unknown
- 2024-07-24 EP EP24748607.9A patent/EP4750532A1/en active Pending
- 2024-07-24 AU AU2024300993A patent/AU2024300993A1/en active Pending
- 2024-07-24 CN CN202480048237.9A patent/CN121712799A/zh active Pending
- 2024-07-24 CR CR20260033A patent/CR20260033A/es unknown
- 2024-07-24 WO PCT/EP2024/070950 patent/WO2025021838A1/en not_active Ceased
- 2024-07-24 KR KR1020267005374A patent/KR20260044221A/ko active Pending
- 2024-07-25 TW TW113127668A patent/TW202519549A/zh unknown
- 2024-07-25 US US18/784,587 patent/US20250092136A1/en active Pending
- 2024-07-26 AR ARP240101982A patent/AR133383A1/es unknown
-
2025
- 2025-12-24 IL IL325601A patent/IL325601A/en unknown
-
2026
- 2026-01-20 CL CL2026000173A patent/CL2026000173A1/es unknown
- 2026-01-22 MX MX2026000851A patent/MX2026000851A/es unknown
- 2026-01-26 CO CONC2026/0000799A patent/CO2026000799A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20260581A1 (es) | 2026-03-11 |
| US20250092136A1 (en) | 2025-03-20 |
| EP4750532A1 (en) | 2026-06-03 |
| CL2026000173A1 (es) | 2026-02-20 |
| CO2026000799A2 (es) | 2026-02-13 |
| IL325601A (en) | 2026-02-01 |
| AU2024300993A1 (en) | 2026-01-22 |
| MX2026000851A (es) | 2026-03-02 |
| WO2025021838A1 (en) | 2025-01-30 |
| TW202519549A (zh) | 2025-05-16 |
| CR20260033A (es) | 2026-02-05 |
| KR20260044221A (ko) | 2026-04-01 |
| CN121712799A (zh) | 2026-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR122761A1 (es) | Moléculas de unión a antígeno biespecíficas anti-cd3 / anti-cd28 | |
| PE20230835A1 (es) | Anticuerpos que se unen a cd3 | |
| AR111203A1 (es) | Inmunoconjugados | |
| AR128686A1 (es) | MOLÉCULAS DE UNIÓN CONTRA FRa | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| AR115419A1 (es) | Anticuerpos anti-tmeff2 monoespecíficos y multiespecifícos y sus usos | |
| AR129935A1 (es) | Anticuerpo, enlazadores, carga activa, conjugados y aplicaciones de los mismos | |
| AR123537A1 (es) | Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca | |
| PE20230616A1 (es) | Anticuerpos que se unen a cd3 y folr1 | |
| AR123728A1 (es) | Anticuerpos cd1a y su uso | |
| AR125074A1 (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso | |
| AR127298A1 (es) | Anticuerpos que se unen a cd30 y cd3 | |
| AR116937A1 (es) | Anticuerpo monoclonal que se une específicamente al antígeno cd20 | |
| AR131527A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR131055A1 (es) | Anticuerpos anti-papp-a y métodos de uso de estos | |
| AR122286A1 (es) | Anticuerpos potenciadores del factor h y usos de estos | |
| AR132159A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR131528A1 (es) | Anticuerpos anti-b7h3 y métodos de uso | |
| AR133492A1 (es) | Agentes de unión a enpp3 y cd3 y métodos de uso de estos | |
| AR132041A1 (es) | Anticuerpos cd16a y métodos de uso | |
| AR134580A1 (es) | ANTICUERPOS DE CD33, ANTICUERPOS MULTIESPECÍFICOS DE CD33 / Vd2 Y USOS DE ESTOS | |
| AR134772A1 (es) | Anticuerpos que se unen a ceacam5 | |
| AR133487A1 (es) | ANTICUERPOS ANTI-PROTEÍNA A-b, MÉTODOS Y USOS DE ESTOS | |
| AR132668A1 (es) | Anticuerpos capaces de unirse a ox40, variantes de los mismos y usos de los mismos | |
| AR130865A1 (es) | Agentes de unión de msln y cd3 y métodos de uso de estos |